![Mark E. Kaufmann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark E. Kaufmann
Directeur Général chez The Linguist Institute, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Elizabeth Grammer | F | 60 | 12 ans | |
William Bertrand | M | 59 | 9 ans | |
Richard Rodgers | M | 57 | 10 ans | |
Onaiza Cadoret-Manier | F | 60 | 4 ans | |
Robert Bazemore | M | 56 | 8 ans | |
Robert Blanks | M | 64 | 11 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Dominique Charmot | M | 69 | 7 ans | |
Peter G. Schultz | M | 67 | 8 ans | |
Christiane Quiniou | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 8 ans |
Gordon Ringold | M | 73 | 7 ans | |
David Collier | M | 61 | - | |
Jan Lundberg | M | 71 | 6 ans | |
Keith Santorelli | M | - | - | |
Jean M. Fréchet | M | - | 7 ans | |
Annalisa Jenkins | M | 58 | 5 ans | |
Geoffrey A. Block | M | 58 | 4 ans | |
Sylvain Chemtob | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 8 ans |
Narani Arasaratnam | F | - | 2 ans | |
Paul Korner | M | 58 | 1 ans | |
Jeremy S. Caldwell | M | 55 | 4 ans | |
Carl Nicolino | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
Shawn Barney | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
Isabelle Dufresne | F | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 4 ans |
Reginald Seeto | M | 52 | 2 ans | |
Ela Borenstein | F | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 4 ans |
Bogdan Dziurzynski | M | 75 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
Steven M. Kaufmann | M | - |
The Linguist Institute, Inc.
![]() The Linguist Institute, Inc. Internet Software/ServicesTechnology Services The Linguist Institute, Inc. operates web and mobile language learning platform. It provides e-learning services. The company was founded by Mark E. Kaufmann and Steven M. Kaufman in 2007 and is headquartered in West Vancouver, Canada. | - |
Jean-Paul Castaigne | M | 79 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 7 ans |
Jamie Stiff | M | - |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 4 ans |
Christopher Henney | M | 83 |
Allostera Pharma, Inc.
![]() Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 3 ans |
Bryan Shaw | M | 70 | 1 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 20 | 64,52% |
Canada | 11 | 35,48% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Mark E. Kaufmann
- Réseau Personnel